Crohn's Disease

High expression of ACE2 and TMPRSS2 in the small intestines may support gastrointestinal-correlated replication of SARS-COV-2, according to a study published in Gastroenterology.

Adverse pregnancy outcomes among women with inflammatory bowel disease on biologic therapy were comparable to that of the general population, according to study results.

Additional, extended treatment with mirikizumab helped produce a clinical response in patients with ulcerative colitis who initially did not respond to treatment, according to study results.

Data from six phase 2/3 studies showed that Stelara had a favorable safety profile through 1-year of treatment in Crohn’s disease and ulcerative colitis, according to research published in Inflammatory Bowel Diseases.

Long-term data from the GEMINI trial showed that Entyvio maintained its favorable safety profile in patients with inflammatory bowel disease over 8 years. It was the top story in gastroenterology last week.

Patients who received Entyvio or Stelara for inflammatory bowel disease who had more comorbidities were at increased risk for hospitalization and infection, according to research published in Alimentary Pharmacology & Therapeutics.

Remicade plus optimized thiopurine was superior in patients with Crohn’s disease compared with infliximab monotherapy for response initiation, durability and clinical outcomes in the first 6 months after induction, according to recently published study results.

The safety profile of Entyvio remained favorable through 8 years of use in patients with inflammatory bowel disease, according to results from the GEMINI long-term safety study.

Healio Gastroenterology presents the following reports on the most recent research in endoscopy.

Patients with inflammatory bowel disease treated with anti-TNF either as a monotherapy or in combination with thiopurines are at increased risk for lymphoma, according to study results.